PTC THERAPEUTICS, INC.

Form 4 June 10, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

subject to Section 16. Form 4 or Form 5 obligations may continue.

Check this box

if no longer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person * **Boulding Mark Elliott**

Symbol

5. Relationship of Reporting Person(s) to

Issuer

below)

PTC THERAPEUTICS, INC.

2. Issuer Name and Ticker or Trading

[PTCT]

(Check all applicable)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 06/08/2015

Director 10% Owner X_ Officer (give title _ Other (specify

Exec VP and CLO

C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT

(Street)

(First)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

SOUTH	PI A	INFIFI	DI	JI.	07080

(City)	(State)	(Zip) Tabl	le I - Non-E	Derivative :	Securi	ties Acqu	ired, Disposed of	, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Ownership Beneficially Form: Dir Owned (D) or Following Indirect (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	06/08/2015		M(1)	12,083	A	\$ 10.85	23,176	D	
Common Stock	06/08/2015		M(1)	50,000	A	\$ 10.85	73,176	D	
Common Stock	06/08/2015		S <u>(1)</u>	10,776	D	\$ 53.87 (2)	62,400	D	
Common Stock	06/08/2015		S <u>(1)</u>	18,324	D	\$ 54.7 (3)	44,076	D	
	06/08/2015		S(1)	24,609	D		19,467	D	

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Common Stock					\$ 55.62 (4)		
Common Stock	06/08/2015	S(1)	3,140	D	\$ 56.42 (5)	16,327	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secur Secur Acqu or Di (D)	rities nired (A) sposed of c. 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 10.85	06/08/2015		M <u>(1)</u>		12,083	<u>(6)</u>	05/15/2023	Common Stock	12,083
Stock Option (Right to Buy)	\$ 10.85	06/08/2015		M <u>(1)</u>		50,000	<u>(7)</u>	05/15/2023	Common Stock	50,000
Stock Option (Right to Buy)	\$ 27.05						<u>(8)</u>	01/27/2024	Common Stock	80,000
Stock Option (Right to Buy)	\$ 51						<u>(9)</u>	01/01/2025	Common Stock	85,600
Stock Option (Right to Buy)	\$ 218.4						(10)	01/10/2022	Common Stock	191

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Stock Option (Right to Buy)	\$ 490.8	<u>(11)</u>	04/27/2021	Common Stock	233
Stock Option (Right to Buy)	\$ 1,149.6	<u>(11)</u>	02/02/2020	Common Stock	200
Stock Option (Right to Buy)	\$ 451.2	<u>(11)</u>	05/15/2019	Common Stock	233
Stock Option (Right to Buy)	\$ 735.6	<u>(11)</u>	04/01/2018	Common Stock	195
Stock Option (Right to Buy)	\$ 735.6	<u>(11)</u>	01/25/2018	Common Stock	166
Stock Option (Right to Buy)	\$ 626.4	<u>(11)</u>	04/18/2017	Common Stock	216
Stock Option (Right to Buy)	\$ 392.4	(11)	03/01/2016	Common Stock	101

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
Boulding Mark Elliott C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080			Exec VP and CLO				
Signatures							
/s/ Colleen Diver Johnson, attorney-in-fact		06/10/20	15				
**Signature of Reporting Person		Date					

Reporting Owners 3

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person for the primary purposes of diversification.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.26 (2) to \$54.25 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$54.26 to \$55.19 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$55.26 (4) to \$56.21 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$56.29 to \$56.63 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on December 31, 2013 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on January 31, 2014.
- This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on May 15, 2014 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on June 15, 2014.
- This option was granted on January 28, 2014 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2015 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015.
- This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
- This option was granted on January 10, 2012 and vests over four years, with 25% of the shares underlying the option vested on January (10) 1, 2013 and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2013.
- (11) Currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.